FGF21 and metabolic dysfunction-associated steatotic liver disease: We identified patients with increased (N = 117, 30%), decreased (N = 159, 40%) or unchanged FGF21 expression (N = 120, 30%), and by comparing the genomes of the three cohorts, we decoded molecular circuitries of FGF21 and identified potentially new therapeutic targets in MASLD.